Z Squared ZSQR
NASDAQ ZSQR
$3.60 +0.00 (+0.00%)
As of: Oct 22, 2026 · 9:33 AM EDT

Z Squared (ZSQR) EBITDA Margin (2025 - 2026)

Updated

Z Squared's EBITDA Margin was -809.21% in Q2 2026, up 2372.04 percentage points from the prior quarter.

Analysis

Z Squared (ZSQR) EBITDA Margin (2025 - 2026) Analysis & Trends

On a trailing twelve-month basis, Z Squared's EBITDA Margin was -705.00% through Jun 30, 2026, up 11797.09 percentage points year-over-year; for FY2025, it was -870.28%.

  • EBITDA Margin shows a four-year change of +17261.08 percentage points (FY2021 to FY2025).
  • In earlier years, EBITDA Margin was -18131.36% in FY2021.
  • Quarterly EBITDA Margin has moved between -5982.89% (Q1 2025) and -196.39% (Q4 2025) over five years.
  • Per Business Quant data, ZSQR's EBITDA Margin in the three quarters before Q2 2026 was -3181.25% (Q1 2026), -196.39% (Q4 2025) and -670.11% (Q3 2025).
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) EBITDA Margin (Qtr)
1 Eli Lilly 1,149.64 Bn 1,118.23 Bn 19.71 Bn 53.49%
2 Johnson & Johnson 626.55 Bn 545.08 Bn 17.26 Bn 35.95%
3 AbbVie 498.79 Bn 471.91 Bn 12.70 Bn 49.01%
4 Merck 371.66 Bn 326.04 Bn 12.21 Bn 6.02%
5 Novartis Ag 299.96 Bn 263.95 Bn 11.24 Bn -
6 Astrazeneca 263.22 Bn 236.91 Bn 12.86 Bn 33.11%
7 Amgen 237.03 Bn 192.43 Bn 7.24 Bn 46.01%
8 Gilead Sciences 191.20 Bn 165.40 Bn 6.22 Bn -124.26%
9 Pfizer 170.83 Bn 117.47 Bn 10.94 Bn 39.16%
10 Z Squared 177.64 Mn 150.88 Mn -1.77 Mn -809.21%
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 -809.21%
Mar 31, 2026 -3,181.25%
Dec 31, 2025 -196.39%
Sep 30, 2025 -645.69%
Mar 31, 2025 -5,824.03%
API Access

Z Squared EBITDA Margin API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=ebitda-margin&ticker=ZSQR&period=max&api_key=YOUR_API_KEY